This prospective cohort study of 196,129 women quantifies atypical femur fracture risk versus hip fractures prevented across 1–10 years of bisphosphonate use. Findings are stratified by race and treatment duration to enable individualized patient counseling. It directly addresses whether atypical femur fracture fears justify reduced bisphosphonate prescribing.
This prospective cohort study of 196,129 women quantifies atypical femur fracture risk versus hip fractures prevented across 1–10 years of bisphosphonate use. Findings are stratified by race and treatment duration to enable individualized patient counseling. It directly addresses whether atypical femur fracture fears justify reduced bisphosphonate prescribing.